Stroke is a leading cause of disability and the second most common cause of death worldwide, with its incidence increasing due to an aging population. Early diagnosis is crucial for timely medical intervention. Biomarkers serve as objective indicators to predict outcomes, monitor treatment responses, and assess prognosis. This review examines the evolving landscape of stroke biomarkers, highlighting their potential clinical applications and the challenges hindering their widespread use. Blood biomarkers are readily accessible and provide insight into the pathophysiological processes underlying stroke. This review focuses on neuronal and glial biomarkers, as well as those associated with inflammation, thrombosis, excitotoxicity, and neuroprotection. Also, it focuses on genetic biomarkers. The timing of biomarker measurement is particularly critical in the early stages of stroke, when rapid decision-making is essential, and it requires systematic investigation. Although numerous molecules have been proposed as stroke biomarkers in recent years, none have yet been integrated into routine clinical practice. Stroke biomarkers hold great promise for enhancing diagnosis, risk stratification, and personalized treatment strategies. However, well-designed studies and rigorous validation are necessary to bridge the gap between research findings and clinical implementation. Integrating biomarkers with existing diagnostic tools could revolutionize stroke management and improve patient outcomes. Continued research into blood biomarkers and their clinical utility remains imperative for advancing stroke care.

Internal carotid artery agenesis is a rare anomaly that can be clinically asymptomatic. Klippel-Feil syndrome is a skeletal malformation characterized by vertebral fusion. Presence of postaxial polydactyly is suggestive of an underlying syndrome. We report a rare case of a 44-year-old patient with non-specific symptoms and an association between these three rare abnormalities. Vascular anomalies were found using intracranial MR angiography and multi-detector CT angiography of the supraaortic arteries. Presence of a single aforementioned anomaly requires cautious imaging assessment in order to detect possible associated anomalies and avoid diagnostic pitfalls. A possible common genetic background could explain the coexistence of these three anomalies.

BACKGROUND:An aneurysm of the superior mesenteric artery (SMA) with a diameter of 2.2 cm was found incidentally on an ultrasound (US) examination in a 26-year-old woman. The only known risk factor was an intracranial aneurysm that was found on her gr...

Weighted average dual-energy computed tomography (DE-CT) reconstructions are considered a proxy of standard CT images of the brain, recommended for routine clinical use and used as a reference standard in DE-CT research. However, their image quality has not been assessed, which was the aim of our study. Images from 81 consecutive patients who underwent both non-contrast single-energy (SE)-CT and DE-CT of the brain on the same scanner were retrospectively evaluated. Attenuation values (HU) and SD of grey matter/white matter (GM/WM) pairs, along with SD in the posterior fossa and subcalvarial region were measured. Four readers evaluated image noise, GM/WM contrast, posterior fossa and subcalvarial artefacts, as well as overall image quality. Weighted average DE-CT GM and WM HU were significantly lower and noise higher compared to SE-CT (GM HU 36.46 v. 41.82; WM HU 28.18 v. 29.94; GM SD 2.93 v. 2.49; and WM SD 3.16 v. 2.44, all p < 0.0001). After correcting the measured SE-CT noise for 37% higher acquisition dose, DE-CT GM noise became significantly lower (2.93 v. 3.11, p = 0.0121). Measured and dose corrected SE-CT GM/WM contrast-to-noise ratio was superior to weighted average DE-CT (3.42 and 2.74 v. 1.95, both p < 0.0001). Weighted average DE-CT had significantly less artifacts on qualitative analysis. Weighted average DE-CT images of the brain yield less artefacts at 37% dose reduction and lower noise at SE-CT equivalent dose. Dose-adjusted GM/WM contrast-to-noise ratio of weighted average DE-CT with 0.4 weighting factor remains inferior to SE-CT images.

Stroke is characterized by a sudden onset of neurological deficit attributed to a focal brain injury. The main treatments for patients with an acute ischemic stroke are intravenous thrombolysis and mechanical thrombectomy. Recanalization therapies have significantly improved patient outcomes; however, their effectiveness depends on a range of pathophysiological factors. This prospective observational study included 60 patients with acute ischemic stroke. The control group consisted of 20 healthy blood donors. Patients were divided into three groups based on whether they received intravenous thrombolysis, mechanical thrombectomy, or combination therapy. We investigated differences between recanalization therapies in patients with ischemic stroke with respect to peripheral blood concentrations of the proinflammatory cytokine interleukin (IL)-18 and endothelial glycocalyx degradation products: syndecan-1, heparan sulphate, and hyaluronic acid, measured by enzyme-linked immunosorbent assay. The blood samples were collected before, 24, and 48 h after recanalization therapy. The concentration of IL-18, syndecan-1, and heparan sulphate increased statistically significantly in patients treated with mechanical thrombectomy. The concentration of hyaluronic acid increased statistically significantly in patients treated with intravenous thrombolysis. The findings primarily reflect between-group differences. Our findings indicate that IL-18 has a significant role in the early inflammatory response. IL-18 and EG degradation products represent potential biomarkers for identifying high-risk patients. Their measurement could help improve the treatment, recovery, and outcomes in patients with acute ischemic stroke. The aforementioned observations underscore their potential value as biomarkers for future research.